Literature DB >> 25365091

Neuropsychiatric questionnaires in systemic lupus erythematosus.

C Tani1, L Palagini, M F Moraes-Fontes, L Carli, M Mauri, S Bombardieri, M Mosca.   

Abstract

Patients with systemic lupus erythematosus (SLE) can be affected by a multitude of neurologic and psychiatric symptoms with a wide range of prevalence and severity. Irrespectively from attribution to SLE or other causes, neuropsychiatric (NP) symptoms strongly impact short-term and long-term outcomes, thus NP evaluation during routine clinical practice in SLE should be undertaken regularly. The assessment of NP involvement in SLE patients is challenging and the available diagnostic tools fail to guarantee optimal diagnostic accuracy, sensitivity to changes as well as feasibility in routine clinical care. Standardised questionnaires (both physician-administered and self-reported) can offer valuable help to the treating physician to capture all possible NP syndromes; few SLE-specific NP questionnaire have been developed but validation in large cohort or cross-cultural adaptations are still pending. On the other hand, general instruments have been largely applied to SLE patients. Both kinds of questionnaires can address all possible NP manifestations either globally or, more frequently, focus on specific NP symptoms. These latter have been mainly used in SLE to detect and classify mild and subtle symptoms, more likely to be overlooked during routine clinical assessment such as headache, cognitive impairment and psychiatric manifestations. In conclusion, this literature review highlights a clear case for validation studies in this area and the wider implementation of questionnaires to assess NP involvement is still warranted. The broader use of such instruments could have important consequences; first of all, by standardising symptom assessment, a better definition of the prevalence of NP manifestation across different centres could be achieved. Secondly, prospective studies could allow for the evaluation of clinical significance of mild symptoms and their impact on the patient's function and quality of life.

Entities:  

Mesh:

Year:  2014        PMID: 25365091

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

Review 1.  Cognitive Impairment in SLE: Mechanisms and Therapeutic Approaches.

Authors:  Aida Zarfeshani; Kaitlin R Carroll; Bruce T Volpe; Betty Diamond
Journal:  Curr Rheumatol Rep       Date:  2021-03-29       Impact factor: 4.592

Review 2.  Multiple Sclerosis: Diagnosis and Differential Diagnosis.

Authors:  Sami Ömerhoca; Sinem Yazici Akkaş; Nilüfer Kale İçen
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

3.  The Montreal Cognitive Assessment Test: A Useful Tool in Screening of Cognitive Impairment in Patients With Systemic Lupus Erythematosus.

Authors:  Nicolas Paez-Venegas; Bethel Jordan-Estrada; Efrain Chavarria-Avila; Felipe Perez-Vazquez; Eduardo Gómez-Bañuelos; Rafael Medina-Dávalos; José-Ángel Ontiveros-González; Gustavo-Ignacio Diaz-Rubio; Rosa E Navarro-Hernandez; Mónica Vázquez-Del Mercado
Journal:  J Clin Rheumatol       Date:  2019-12       Impact factor: 3.517

4.  Cognitive dysfunction among people with systemic lupus erythematosus is associated with reduced participation in daily life.

Authors:  Moon Young Kim; Deepali Sen; Ronald R Drummond; Matthew C Brandenburg; Kathryn Lp Biesanz; Alfred Hj Kim; Seth A Eisen; Carolyn M Baum; Erin R Foster
Journal:  Lupus       Date:  2021-04-01       Impact factor: 2.911

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.